Meeting
2015 ASCO Annual Meeting
NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.
Authors
Steven J. Chmura
The University of Chicago Hospitals, Chicago, IL
Steven J. Chmura , Kathryn A. Winter , Joseph Kamel Salama , Wendy A. Woodward , Virginia F. Borges , Hania A Al-Hallaq , Martha Matuszak , Nora T. Jaskowiak , Michael T. Milano , Hanna Bandos , Julia R. White
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Local Therapy
Clinical Trial Registration Number
Pending
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS1105)
DOI
10.1200/jco.2015.33.15_suppl.tps1105
Abstract #
TPS1105
Poster Bd #
216b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).
First Author: Steven J. Chmura
Poster
2024 ASCO Genitourinary Cancers Symposium
Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN).
First Author: Giulio Francolini
Poster
2023 ASCO Annual Meeting
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
First Author: Mark Charles Korpics
Poster
2023 ASCO Annual Meeting
High dose alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Results from the randomized phase 3 OLIGO study.
First Author: Annemiek Van Ommen-Nijhof